Metformin regulates the LIN28Bmediated JNK/STAT3 signaling pathway through miR1403p in subretinal fibrosis

Zhijuan Hua1,2, Wenchang Yang1, Dongli Li1

  • 1Department of Ophthalmology, The First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan 650032, P.R. China.

Insights

Metformin shows promise in treating subretinal fibrosis (SF) by regulating microRNA-140-3p and LIN28B. This mechanism inhibits oxidative stress and fibrosis, offering a potential new therapeutic avenue for vision loss.

Area of Science:

  • Ophthalmology
  • Molecular Biology
  • Pharmacology

Background:

  • Subretinal fibrosis (SF) causes irreversible vision loss due to submacular neovascularization.
  • Current treatments for SF are limited, highlighting the need for novel therapeutic strategies.

Purpose of the Study:

  • To investigate the therapeutic potential of metformin in subretinal fibrosis (SF).
  • To elucidate the underlying mechanism involving microRNA-140-3p (miR-140-3p)/LIN28B/JNK/STAT3 signaling in regulating oxidative stress, angiogenesis, and fibrosis.

Main Methods:

  • Established laser-induced SF in mice and a TGF-β1-induced ARPE-19 fibrotic cell model.
  • Utilized cell viability assays, flow cytometry for reactive oxygen species, western blotting for protein analysis, and RT-qPCR for gene expression.
  • Performed dual-luciferase and coimmunoprecipitation assays to confirm molecular interactions.

Main Results:

  • Metformin promoted miR-140-3p and inhibited LIN28B expression in ARPE-19 cells, suppressing JNK/STAT3 activation, oxidative stress, EMT, and fibrosis.
  • LIN28B overexpression or JNK/STAT3 activation partially reversed metformin's inhibitory effects.
  • Confirmed miR-140-3p targets LIN28B, and LIN28B interacts with JNK to regulate the JNK/STAT3 pathway.

Conclusions:

  • Metformin alleviates SF by upregulating miR-140-3p, downregulating LIN28B, and subsequently inhibiting the JNK/STAT3 pathway.
  • This pathway modulation reduces oxidative stress and fibrotic processes, suggesting metformin as a potential treatment for SF.

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.6K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
8.9K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K